Assess whether a CMC change is a comparability or a new product (8bb108)

Situation

A CMC change is sits with CMC change-control owner because a site-change that invalidates stability claims hit a mid-size sponsor after a complete response letter. Evidence is biosimilar analytical similarity report; write the Pharma & Life Sciences Pharmacovigilance option that extract can carry.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using biosimilar analytical similarity report after a site-change that invalidates stability claims.

Hypotheses to test

• Biosimilar analytical similarity report reads as A CMC change is a comparability once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population.
• Biosimilar analytical similarity report is closer to A new product after a site-change that invalidates stability claims; A CMC change is a comparability would over-claim this Pharmacovigilance extract.
• A dual reading is still live in biosimilar analytical similarity report for CMC change-control owner in a mid-size sponsor after a complete response letter.
• Biosimilar analytical similarity report is missing the fact CMC change-control owner needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether biosimilar analytical similarity report supports the labeled claim CMC change-control owner would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a site-change that invalidates stability claims and write the one fact that would move a CMC change is for CMC change-control owner.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a site-change that invalidates stability claims). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.